# Søren Møller

> Søren Møller is a Series A investor at Novo Holdings backing Biotechnology. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Novo Holdings](https://shizune.co/investors/profile/novo-a-s)
- Location: Copenhagen, Denmark
- Total investments: 12
- Last investment: Jan 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/s%C3%B8ren-m%C3%B8ller-5545b83

Søren Møller is a Series A investor at Novo Holdings in Copenhagen focused on Biotechnology and Biopharma. Søren joined Novo A/S in October 2011 as Managing Investment Director of Novo Seeds.Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford UniversitySchool of Medicine.Prior to joining Novo Seeds, Søren served as global manager of Bioinformatics and Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S where he was responsible for development of microRNA based products for life science research, pharma services and diagnostics. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.Søren serves on the Board of Directors of Reapplix A/S and Denator AB. And since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark).

## Contacts

5 contacts available for Søren Møller: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/sren-mller?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $7M–$8.4M |
| Series A | $4.4M–$93M |
| Series B | $12M–$39M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 50% |
| Biopharma | 3 | 25% |
| Therapeutics | 3 | 25% |
| Medical | 2 | 17% |
| Health Care | 2 | 17% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 33% |
| Seed | 2 | 17% |
| Series B | 2 | 17% |
| Pre-Seed | 1 | 8% |
| Series C | 1 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 5 | 42% |
| India | 1 | 8% |
| Sweden | 1 | 8% |
| United Kingdom | 1 | 8% |
| The Netherlands | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Orbis Medicines | Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery. | $93.5M | Series A | Jan 06, 2025 | https://www.orbismedicines.com |
| LiteStore | Memory updated LiteStore is a Flexi-Retail platform that connects popular brands with retail spaces |  | Venture - Series Unknown | Jan 01, 2024 | https://www.litestore.in/ |
| Biosyntia | Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen. | $11.7M | Series B | Jul 06, 2022 | http://biosyntia.com |
| 21st.BIO | 21st Bio has the potential to replace and improve a wide range of meals and materials with appealing sustainable bio-based alternatives. | $97.1M | Venture - Series Unknown | Dec 21, 2021 | https://21st.bio/ |
| NorthSea Therapeutics | NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $80M | Series C | Dec 17, 2021 | https://www.northseatherapeutics.com/ |
| Asgard Therapeutics | Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells. | $7M | Seed | Nov 09, 2021 | http://www.asgardthx.com/ |
| Odin | Odin enables seamless fundraising from your network in just a few clicks, taking care of all legal and administrative tasks. The platform collaborates with founders, angel syndicates, and emerging fund managers worldwide. It supports investors from almost any location, manages SPVs, handles complex carried interest arrangements, and more. Futureplans include enabling users to raise entire funds on Odin (not just deal-by-deal SPVs) and providing a feature for discovering and joining investment clubs directly through the platform. |  | Pre-Seed | Sep 01, 2021 | https://www.joinodin.com/ |
| Muna Therapeutics | Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's. | $73M | Series A | Jul 09, 2021 | https://munatherapeutics.com/ |
| Bactolife | Bactolife helps in developing innovative solutions meeting the global need for reducing antimicrobial resistance. Its products are based on minimizing the risk of disease through reduction of virulence, making pathogens unable to establish an active infection. | $8.4M | Seed | Apr 19, 2021 | http://www.bactolife.com/ |
| NorthSea Therapeutics | NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $39.5M | Series B | Jan 08, 2020 | https://www.northseatherapeutics.com/ |

10 of 12 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 7 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 4 deals together
- [Haatch](https://shizune.co/investors/profile/haatch) — VC Fund, 4 deals together
- [New Science Ventures](https://shizune.co/investors/profile/new-science-ventures) — VC Fund, 4 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 3 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 2 deals together

## About Novo Holdings

VC Fund · Hellerup, Denmark

Novo Holdings is a holding and investment firm that manages the assets of the Novo Nordisk Foundation. It is a life science investor with a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments.

5 contacts available at Novo Holdings.

| Name | Title | Profile |
| --- | --- | --- |
| Emmanuelle Coutanceau | Partner Novo Seeds | https://shizune.co/investors/profile/emmanuelle-coutanceau |
| Thomas Dyrberg | Partner | https://shizune.co/investors/profile/thomas-dyrberg |
| Thomas Grotkjær | Investor & Principal | https://shizune.co/investors/profile/thomas-grotkj%C3%A6r |
| Abhijeet Lele | Senior Partner and Head of US Principal Investments | https://shizune.co/investors/profile/abhijeet-lele |
| Christopher Shen | Partner | https://shizune.co/investors/profile/christopher-shen |

## Similar investors

### Similar industry
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [British Business Investments](https://shizune.co/investors/profile/british-business-investments) — VC Fund
- [White Star Capital](https://shizune.co/investors/profile/white-star-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund

## Featured in investor lists
- [Venture Capital Angel Investors in United Kingdom](https://shizune.co/investors/venture-capital-angel-investors-united-kingdom)
- [Venture Capital Angel Investors in Europe](https://shizune.co/investors/venture-capital-angel-investors-europe)

## FAQ

### What does Søren Møller invest in?

Søren Møller invests primarily in Biotechnology, Biopharma and Therapeutics startups, most often at Series A and Seed stage. Most of the 12 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Søren Møller's check size?

Søren Møller typically joins rounds of $7M–$8.4M at Seed, $4.4M–$93M at Series A and $12M–$39M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Søren Møller participates in.

### How do I contact Søren Møller?

Public channels for Søren Møller include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Søren Møller last invest?

The most recent investment recorded for Søren Møller closed in Jan 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co